<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112454894</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112454894</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Tadalafil in pulmonary hypertension: May be more than seen?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Karasu-Minareci</surname>
<given-names>Edibe</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112454894"/>
<xref ref-type="corresp" rid="corresp1-0960327112454894"/>
</contrib>
<aff id="aff1-0960327112454894">Department of Pharmacology, Faculty of Medicine, Akdeniz University, Antalya, Turkey</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327112454894">Edibe Karasu-Minareci, Department of Pharmacology, Faculty of Medicine, Akdeniz University, 07070 Antalya, Turkey Email: <email>edibekarasu@akdeniz.edu.tr</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>11</issue>
<fpage>1186</fpage>
<lpage>1187</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>I read an interesting article about the superiority of tadalafil over tempol via its antioxidant capacity on acute hypoxia-induced pulmonary hypertension (PH) model.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454894">1</xref>
</sup> Rashid et al. investigated and compared the antioxidant capacity of specific phosphodiesterase type-5 (PDE5) inhibitor, tadalafil, with superoxide dismutase mimetic and an efficient free radical scavenging agent tempol in acute hypoxia-induced PH model. They demonstrated that tadalafil was superior to tempol in inhibiting hypoxia-induced rise in right ventricular systolic pressure (RVSP) without producing any fall in mean arterial pressure. Also, tadalafil was shown to partially prevent oxidative stress. In conclusion, Rashid et al. highlighted the superiority of tadalafil especially in the settings of chronic hypoxia-induced PH.</p>
<p>Monocrotaline (MCT)-induced PH is the other widely accepted animal model in PH studies.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454894">2</xref>
</sup> MCT is a member of the pyrrolizidine alkaloid family of plant toxins, which induces a delayed, yet progressive vascular injury resulting in PH in rats, dogs and monkeys.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112454894">3</xref>,<xref ref-type="bibr" rid="bibr4-0960327112454894">4</xref>
</sup> It is recognized that the initial reaction to MCT-induced PH is injury to the endothelial cells that precedes media hypertrophy in small size pulmonary arteries, and leads to an increase in pulmonary artery disease. These alterations in morphology largely mimic the primary PH in humans.</p>
<p>We have recently compared the effects of three commercially available PDE5 inhibitors: sildenafil, vardenafil and tadalafil in rat MCT-induced PH model.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112454894">5</xref>
</sup> It has been briefly demonstrated that vardenafil was more effective than sildenafil and tadalafil in this model. Vardenafil relaxes pulmonary artery rings in pulmonary hypertensive group through nitric oxide (NO)-cyclic guanosine monophosphate (NO-cGMP)-independent pathway. Neither sildenafil nor tadalafil achieves to induce relaxation response in pulmonary artery rings when NO-cGMP pathway inhibitor (NO synthase inhibitor, <sc>l</sc>-NAME and soluble guanylyl cyclase inhibitor, ODQ) incubations were used. This superiority potentially results from the differences in the heterocyclic ring system of vardenafil.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112454894">6</xref>
</sup> Biochemical potencies (affinities) of these compounds for PDE5 have been determined by half maximal inhibitory concentration (IC<sub>50</sub>) and dissociation rate (<italic>K</italic>
<sub>D</sub>), respectively, were the following: sildenafil (3.7 ± 1.4, 3.7 ± 0.29 nM), tadalafil (1.8 ± 0.40, 1.9 ± 0.37 nM), vardenafil (0.091 ± 0.031, 0.27 ± 0.01 nM), and it has been clearly demonstrated that vardenafil was the most potent inhibitor of PDE-5 because of its slow dissociation rate.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112454894">7</xref>
</sup> Although tadalafil has an advantage over sildenafil and vardenafil because of its longer duration of action, tadalafil did not significantly alter the time to exercise treadmill test-induced ischemia compared with placebo in subjects with coronary artery disease.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112454894">8</xref>
</sup> It is well-known that PH and coronary artery disease share similar risk factors, including endothelial dysfunction, diminishing of NO production and increased oxidative stress. This study is also in agreement with the others demonstrating that tadalafil was less effective than sildenafil and vardenafil in reducing the infarct size.<sup>
<xref ref-type="bibr" rid="bibr9-0960327112454894">9</xref>
</sup> In other preparations such as rat aorta-penile arteries and rabbit isolated pulmonary artery–corpus cavernosum tissue, vardenafil was shown to be more potent than other PDE5 inhibitors in relaxing the vascular tissues and preparations.<sup>
<xref ref-type="bibr" rid="bibr10-0960327112454894">10</xref>
<xref ref-type="bibr" rid="bibr11-0960327112454894"/>–<xref ref-type="bibr" rid="bibr12-0960327112454894">12</xref>
</sup> These discrepancies may be attributed to experimental model, protocols or preparations difference employed in these studies. Also, these studies demonstrated that vardenafil has some beneficial effects in addition to its PDE5 inhibitory activity (e.g. activation of some ion channels or blocking of calcium influx).</p>
<p>For the past three decades, two rodent models have been central to the investigation of human PH: the hypoxia exposure model and the MCT lung injury model. Although the increase in pulmonary arterial pressure and right ventricular hypertrophy were comparable in the rat hypoxia and MCT models, structural analysis of muscular pulmonary arteries reveals major differences between the two models.<sup>
<xref ref-type="bibr" rid="bibr13-0960327112454894">13</xref>
</sup> It has been shown that chronic hypoxia and MCT induce different patterns of pulmonary vascular remodeling. Muscularization of arterioles is seen in both the models; however, medial hypertrophy of muscular pulmonary arteries is more extensive in MCT-treated rats.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112454894">14</xref>,<xref ref-type="bibr" rid="bibr15-0960327112454894">15</xref>
</sup> Although the pathophysiological mechanisms of hypoxic pulmonary vasoconstriction are still under discussion, Rashid et al. should also focus on pulmonary artery responsiveness in vitro and clarify the related mechanisms on the effect of tadalafil in this model. They try to explain the reason for the inhibitory effect of tadalafil on RVSP without changing cardiac output. Reduction in pulmonary vascular resistance was given as an answer for this situation by the authors. To confirm this hypothesis, the next approach would be to investigate the tadalafil-induced alterations in pulmonary tone.</p>
<p>Although I agree with the concept that tadalafil also showed a partial antioxidant action, we should always think and reveal the other possible responsible mechanisms associated with this protective effect.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112454894"><label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112454894">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rashid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kotwani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fahim</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats</article-title>. <source>Hum Exp Toxicol</source> <year>2012</year>; <volume>31</volume>: <fpage>626</fpage>–<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112454894">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minareci-Karasu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ogutman</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Experimental animal models for cardiovascular diseases</article-title>. <source>Turkiye Klinikleri J Cardiovasc Sci</source> <year>2011</year>; <volume>23</volume>(<issue>1</issue>): <fpage>65</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112454894">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoorn</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>RA.</given-names>
</name>
</person-group> <article-title>Monocrotaline pyrrole alters DNA, RNA and protein synthesis in pulmonary artery endothelial cells</article-title>. <source>Am J Physiol</source> <year>1992</year>; <volume>262</volume>: <fpage>L740</fpage>–<lpage>L747</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112454894">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lame</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Morin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Segall</surname>
<given-names>HJ</given-names>
</name>
</person-group>. <article-title>Monocrotaline metabolism and distribution in fisher 344 and sprague dawley rats</article-title>. <source>Comp Biochem Physiol</source> <year>1997</year>; <volume>117</volume>: <fpage>115</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112454894">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minareci-Karasu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ozbudak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ozbilim</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sadan</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension</article-title>. <source>SciWorld J</source>. <comment>Doi: 10.1100/2012/718279</comment>.</citation>
</ref>
<ref id="bibr6-0960327112454894">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbin</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Beasley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blount</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>SH</given-names>
</name>
</person-group>. <article-title>Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific PDE-5</article-title>. <source>Neurochem Int</source> <year>2004</year>; <volume>45</volume>: <fpage>859</fpage>–<lpage>863</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112454894">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blount</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Beasley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zoraghi</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Binding of tritiated sildenafil, tadalafil or vardenafil to the PDE-5 catalytic side displays potency, specificity, heterogeneity and cGMP stimulation</article-title>. <source>Mol Pharmacol</source> <year>2004</year>; <volume>66</volume>: <fpage>144</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112454894">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kloner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Effron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Emmick</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease</article-title>. <source>Br J Clin Pharmacol</source> <year>2005</year>; <volume>60</volume>: <fpage>459</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112454894">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richmond</surname>
<given-names>VA</given-names>
</name>
</person-group>. <article-title>Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart</article-title>. <source>Int J Imp Res</source> <year>2006</year>; <fpage>1</fpage>–<lpage>2</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112454894">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Villalba</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Mechanisms of the relaxant effect of vardenafil in rat penile arteries</article-title>. <source>Eur J Pharmacol</source> <year>2008</year>; <volume>586</volume>: <fpage>283</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112454894">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toque</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Priviero</surname>
<given-names>FBM</given-names>
</name>
<name>
<surname>Morganti</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Antunes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nucci</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets</article-title>. <source>Br J Pharmacol</source> <year>2008</year>; <volume>154</volume>: <fpage>787</fpage>–<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112454894">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Adaikan</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum</article-title>. <source>Eur J Pharmacol</source> <year>2006</year>; <volume>541</volume>: <fpage>184</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112454894">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Suylen</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Daemen</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Pulmonary artery remodeling differs in hypoxia and monocrotaline-induced pulmonary hypertension</article-title>. <source>Am J Respir Crit Care Med</source> <year>1998</year>; <volume>157</volume>: <fpage>1423</fpage>–<lpage>1428</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112454894">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Keane</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Suyama</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Pulmonary hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by p-chlorophenylalanine</article-title>. <source>Respiration</source> <year>1985</year>; <volume>47</volume>: <fpage>48</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112454894">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Arroyo</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>A brief overview of Mouse models of pulmonary arterial hypertension: problems and prospects</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <year>2012</year>; <volume>302</volume>: <fpage>L997</fpage>–<lpage>L991</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>